A rational approach to the management of recurrent or persistent ovarian carcinoma

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 114-130

  Thigpen, Tate ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

chemoresistant recurrent disease; chemosensitive recurrent disease

Indexed keywords

ALTRETAMINE; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EC 145; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; NAVELBINE; OLAPARIB; PACLITAXEL; PEMETREXED; PLATINUM; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CHRONIC PAIN; CLINICAL TRIAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DECISION MAKING; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PACLITAXEL; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857561301     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31824b9bc5     Document Type: Article

References (63)

1. Cancer Facts and Figures 2012, American Cancer Society, 2012.
2. Kurman RJ, Shih LM. The origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am J Surg Path. 2010;34:433-443.
3. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Path. 2008;39:1239-1251.
4. Bookman M, Brady M, McGuire W, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
5. Mackay HJ, Brady MF, Oza AM, et al. Gynecologic Cancer Intergroup Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945-952.
6. FIGO Committee on Gynecologic Oncology Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3-4.
7. Thigpen T, Brady M, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. Cancer. 1993;71:606-614.
8. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 1992;47:159-166. (Pubitemid 23001322)
9. Tagawa T, Morgan R, Yun Y, et al. Ovarian cancer: opportunity for targeted therapy. J Oncol. 2012. [Epub ahead of print].
10. Thigpen T, DuBois A, McAlpine J, et al. First line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21:756-762.
11. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955. (Pubitemid 26428219)
12. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007. (Pubitemid 32176274)
13. Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354: 34-43. (Pubitemid 43048949)
14. Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
15. Burger R, Brady M, Bookman M, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
16. Kristensen G. Results of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Proc ASCO. 2011;29: 333s(abstr LBA5006).
17. Aghajanian C. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Proc ASCO. 2011;29:333s(abstr LBA5007).
18. Markman M, Liu PY,Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel- based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21: 2460-2465. (Pubitemid 46606325)
19. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200. (Pubitemid 46606249)
20. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334: 1-6. (Pubitemid 26012496)
21. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000;18:106-115. (Pubitemid 30036343)
22. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021-1027. (Pubitemid 20146659)
23. Sevelda P, Vavra N, Schemper M, et al. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer. 1990;65:2349-2352. (Pubitemid 20164847)
24. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol. 1993;169: 40-52. (Pubitemid 23223926)
25. Thigpen JT. Cancers of the ovary and fallopian tubes. In: Abeloff M, Armitage J, Lichter A, et al. Clinical Oncology. 3rd ed. NY: Churchill-Livingstone; 2004.
26. Ozols R. Intraperitoneal therapy in ovarian cancer: time's up. J Clin Oncol. 1991;9:197-199.
27. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112: 256-274.
28. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16: 1324-1330.
29. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9: 389-393.
30. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650-653. (Pubitemid 19111764)
31. Du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1330. (Pubitemid 37160865)
32. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum- sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707. (Pubitemid 46630933)
33. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum- based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361: 2099-2106.
34. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum- sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707. (Pubitemid 46630933)
35. Ferrero J, Weber B, Geay J, et al. Secondline chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse. Ann Oncol. 2007;18:263-268. (Pubitemid 46323091)
36. Pujade-Lauraine E, Wagner U, Aavail- Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28:3323-3329.
37. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322. (Pubitemid 32642183)
38. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896. (Pubitemid 351398081)
39. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum- sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410. (Pubitemid 28135580)
40. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440. (Pubitemid 43729968)
41. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxelresistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135. (Pubitemid 36263370)
42. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1996;14:2546-2551. (Pubitemid 26300122)
43. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992;10:243-248.
44. Look KY, Muss HB, Blessing JA, et al. A phase II trial of 5-fluorouracil andhigh-dose leucovorin in recurrent epithelial ovarian carcinoma.AGynecologic OncologyGroup Study. Am J Clin Oncol. 1995;18:19-22.
45. Vergote I, Micha J, Pippitt C Jr, et al. Phase II study of NKTR-102 in women with platinum resistant/refractory ovarian cancer. Proc ASCO. 2010;28:393s (abstr 5013).
46. Naumann RW, Symanowski J, Ghamande S, et al. PRECEDENT: a randomized phase II trial comparing EC-145 and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in subjectswith platinum-resistant ovarian cancer. Proc ASCO. 2010;28:952s (abstr LBA5012b).
47. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165-5171. (Pubitemid 350237599)
48. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186. (Pubitemid 350232248)
49. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol. 1996;62:4-6. (Pubitemid 26234538)
50. Matei D, Sill W, Lankes H, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol. 2011;29:69-75.
51. Kohn E. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab- naïve epithelialovarian cancerpatients. Proc ASCO. 2011;29:336s(abstr 5019).
52. BookmanM,Darcy K,Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression ofHER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283-290. (Pubitemid 46606157)
53. Hurteau JA, Blessing JA, DeCesare SL, et al. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001;82:7-10. (Pubitemid 32634946)
54. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539-5548. (Pubitemid 41060831)
55. Schilder RJ, Sill MW, Lee RB. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:3418-3425.
56. Garcia AA, Sill MW, Lankes HA, et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011. [Epub ahead of print] doi:10.1016/j.ygyno.2011.10.022.
57. Modesitt SC, Sill M, Hoffman JS, et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-186.
58. Usha L, Sill MW, Darcy KM, et al. A GynecologicOncologyGroup phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011;121:455-461.
59. Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010;116:332-334.
60. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2011 30:372-379.
61. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27:5601-5606.
62. Buckanovitch R. Activity of cabozantinib in advanced ovarian cancer patients: results from a phase II randomized discontinuation trial. Proc ASCO. 2011; 29:334s(abstr 5008).
63. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22:3631-3638. (Pubitemid 41103670)